|
Date
|
Article title
|
Reporter
|
Outlet
|
|
12/4/2019
|
Drug can curb dementia’s delusions, researchers find
|
Marilynn Marchione
|
Associated Press
|
|
12/4/2019
|
What to Watch as Biogen Presents its All-Important Alzheimer's Data
|
Jacob Bell
|
BioPharma Dive
|
|
12/4/2019
|
4 questions key to making sense of new data on Biogen’s resurrected Alzheimer’s drug
|
Rebecca Robbins
|
STAT News
|
|
12/4/2019
|
A resurrection of aducanumab for Alzheimer's disease
|
Lon Schneider
|
The Lancet
|
|
12/5/2019
|
Alzheimer's Drug Discovery Foundation Reacts to Biogen’s New Data on Aducanumab
|
n/a
|
Alzheimer's Drug Discovery Foundation
|
|
12/5/2019
|
New Details Emerge on Drug That May Slow Alzheimer’s Disease
|
Marilynn Marchione
|
Associated Press
|
|
12/5/2019
|
Experts split sharply over experimental Alzheimer’s drug
|
Marilynn Marchione
|
Associated Press
|
|
12/5/2019
|
CTAD 2019: Worth the wait, Acadia’s Nuplazid looks good in dementia-related psychosis
|
Brian Orelli
|
BioWorld
|
|
12/5/2019
|
Biogen Resumes Alzheimer’s Studies to Offer Controversial Drug
|
Michelle Cortez and Robert Langreth
|
Bloomberg
|
|
12/5/2019
|
Biogen Has More Hope Than Data for Alzheimer’s Drug
|
Max Nisen
|
Bloomberg
|
|
12/5/2019
|
Researchers Find Drug Can Curb Delusions in Dementia and Alzheimer’s Patients
|
|
CBSN Los Angeles
|
|
12/5/2019
|
Topline Phase 3 Results for Pimavanserin in Dementia-Related Psychosis
|
Megan Brooks
|
Medscape
|
|
12/5/2019
|
Biogen’s latest Alzheimer’s drug trials will change dementia drug research
|
Katherine Ellen Foley
|
Quartz
|
|
12/5/2019
|
Biogen builds case for its Alzheimer's drug, skeptics say more data needed
|
Deena Beasley, Julie Steenhuysen
|
Reuters
|
|
12/5/2019
|
Skepticism persists about revived Alzheimer’s drug after conference presentation
|
Kelly Servick
|
Science Magazine
|
|
12/5/2019
|
A once-scrapped Alzheimer’s drug may work after all, new analyses suggest
|
Laura Sanders
|
Science News
|
|
12/5/2019
|
Alzheimer's breakthrough as scientists find first drug to slow down the disease
|
Sarah Knapton
|
The Telegraph
|
|
12/5/2019
|
Biogen Details Case for Controversial Alzheimer’s Drug
|
Joseph Walker
|
The Wall Street Journal
|
|
12/5/2019
|
Biogen’s potential new drug for Alzheimer’s disease gets cautiously optimistic review following presentation
|
Fredrick Kunkle
|
The Washington Post
|
|
12/5/2019
|
Is this Alzheimer's drug a breakthrough for millions? Company unveils mixed results
|
Ken Alltucker
|
USA Today
|
|
12/5/2019
|
New Biogen Data: Experimental Alzheimer's Drug At High Dose Slowed Mental Decline
|
Carey Goldberg
|
WBUR 90.1 FM
|
|
12/5/2019
|
Drug Reduces Delusions in Dementia Patients
|
n/a
|
WebMD
|
|
12/6/2019
|
Grifols will address in the US the clinical development of its therapy against Alzheimer's | Companies
|
n/a
|
EN24
|
|
12/6/2019
|
Aducanumab: the beginning of the end of Alzheimer’s disease?
|
Jason Karlawish
|
STAT News
|
|
12/6/2019
|
Biogen Explains How Its Alzheimer’s Drug Went From Poor to Promising
|
Alice Park
|
TIME
|
|
12/6/2019
|
Cassava Sciences' Shares Trade Up 20% on Updated Phase 2a Alzheimer's Data
|
n/a
|
Streetwise Reports
|
ctad@ant-congres.com